Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action.
| Autor: | Wenyan Cai, Jianbo Dong, Kankanamalage, Sachith Gallolu, Titong, Allison, Jiadong Shi, Zhejun Jia, Bo Wang, Cai Huang, Jing Zhang, Jun Lin, Kan, Steven Z., Shuhua Han, Joe Zhou, Yue Liu |
|---|---|
| Zdroj: | Antibody Therapeutics; Oct2021, Vol. 4 Issue 4, p228-241, 14p, 7 Graphs |
| Databáze: | Complementary Index |
| Externí odkaz: |
|